RxDoctor Payments Data

Vijaya Koneru, MD

Internal Medicine · Athens, ALNPI 1750434080

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 9 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 7 manufacturers reported payments, led by Abbott at 36.2% of the total. Reporting peaked in 2023 at $98 and has fallen 81.0% since, to $19 in 2025. That places this record below the midpoint for internal medicine clinicians in AL, where the typical reported total is $372.

$160in general payments, 2019–2025

Across 9 payments — averaging $17.73 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$58
  • Novartis$26
  • Novo Nordisk$19
  • Merck$17
  • Laborie Medical Technologies Corp.$15
  • E.r. Squibb & Sons, L.L.C.$13
  • plus $13 from 1 others

What the payments were for

  • Food & beverage$160100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
23
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$160 in reported general payments places this provider in the 35th percentile of 1,533 internal medicine providers in Alabama.

See all internal medicine providers in Alabama

Medicare billing

Part B allowed, 2024
$58,820
Medicare patients
89
Services billed
958

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JanuviaSitagliptin Phosphate56$64,138
OzempicSemaglutide39$57,786
EliquisApixaban52$54,743
MounjaroTirzepatide37$49,978
JardianceEmpagliflozin37$27,479
FarxigaDapagliflozin Propanediol27$27,236
JanumetSitagliptin Phos/Metformin Hcl24$17,215
Trelegy ElliptaFluticasone/Umeclidin/Vilanter13$15,440
Janumet XrSitagliptin Phos/Metformin Hcl15$12,960
Lantus SolostarInsulin Glargine,hum.Rec.Anlog39$4,567
Pravastatin Sodium169$3,167
Losartan Potassium204$2,428
Omeprazole141$2,225
Amlodipine Besylate340$2,185
Atorvastatin Calcium170$2,078

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
MerckJanuvia, Janumet, Janumet Xr$17$94,31395 claims
Novo NordiskOzempic$19$57,78639 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 35th percentile of 1,533 internal medicine providers in Alabama.

Other internal medicine in Athens

See the full list for Alabama

Where these figures come from

Is this you, or does something look wrong? →